Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, affects roughly 3 million Americans, with most diagnoses occurring before age 35.

This chronic condition causes inflammation in the gastrointestinal tract, but early identification is often delayed because symptoms can mimic other conditions.

Research suggests that IBD may be preceded by a “substantial symptomatic period,” sometimes lasting 10 years or more before standard tests like endoscopy or biopsy confirm the disease.

A 2023 study analyzing Sweden’s national health database found that individuals presenting with IBD-specific symptoms, such as abdominal pain, diarrhea, or rectal bleeding, who initially had a normal endoscopy still faced an elevated risk of developing IBD over the next 30 years.

Specifically, 2.4% of those with a normal lower GI biopsy later developed IBD, compared to 0.4% of those without, equating to one additional diagnosis per 37 people within 30 years.

Dr. Jiangwei Sun, lead author, emphasized the importance of recognizing future risk even after normal endoscopic findings.

Common IBD symptoms include persistent diarrhea, abdominal pain, rectal bleeding, weight loss, and fatigue.

While Crohn’s disease can affect the entire GI tract, ulcerative colitis typically targets the colon and rectum. Despite these differences, symptoms frequently overlap, complicating timely diagnosis.

The insidious progression of IBD contributes to delays. Dr. Stefan Holubar, a colorectal surgeon at Cleveland Clinic, explains that patients often adapt to slowly worsening symptoms until significant bowel damage occurs.

Dr. Jeffrey Berinstein, a gastroenterologist at Michigan Medicine, notes that while the risk of developing IBD after a normal biopsy is elevated, the overall number of affected individuals remains low.

Experts recommend a proactive approach. Individuals at higher risk experiencing mild symptoms should establish care with an IBD specialist for long-term monitoring, aiming for earlier diagnosis and intervention.

Physicians are encouraged to repeat endoscopies if symptoms worsen or fail to respond to treatment, as a negative biopsy does not definitively rule out the disease.

With advances in treatment and understanding, IBD has become a largely manageable condition. Targeted therapies now control inflammation effectively, allowing patients to maintain normal, active lives while mitigating long-term bowel damage.